Clinical role of positron emission tomography (PET) in endocrine tumours

Panminerva Medica

Volumn 44, Issue 3, 2002, Pages 185-196

  Rubello, D ^a   Rufini, V ^b   Casara, D ^a   Calcagni, M L ^b   Samanes Gajate, A M ^b   Shapiro, B ^c  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Adrenal gland neoplasms, radionuclide imaging; Carcinoma, medullary, radionuclide imaging; Fludeoxy glucose F18; Neuroendocrine tumors, radionuclide imaging; Thyroid neoplasms, radionuclide imaging; Tomography, emission computed

Indexed keywords

ADRENAL TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ENDOCRINE TUMOR; GASTROINTESTINAL TUMOR; HUMAN; MEDULLARY CARCINOMA; REVIEW; SCINTISCANNING; THYROID TUMOR;

ADRENAL GLAND NEOPLASMS; CARCINOMA, MEDULLARY; ENDOCRINE GLAND NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036715553     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. rd German interdisciplinary consensus conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med 2001;28:1707-23.
2. DeGroot LJ, Kaplan EL, McCormik M, Strauss F. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414-24.
3. Mazzaferri E, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.
4. 131I scan. Thyroidol, Clin Exp 1997;9:95-100.
5. 99mTc-MIBI scan combined with high resolution neck ultrasonography. Tumori 1999;85:120-5.
6. Rubello D, Mazzarotto R, Casara D. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery. Eur J Nucl Med 2000;27:431-40.
7. Casara D, Rubello D, Saladini G, DeBesi P, Fassina A, Busnardo B. Differentiated thyroid carcinoma in the elderly. Aging, Clin Exp Res 1992;4:333-9.
8. Rubello D, Girelli ME, Casara D, Piccolo M, Perin A, Busnardo B. Usefulness of combined anti-thyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest 1990;13:737-42.
9. Rubello D, Casara D, Girelli ME, Piccolo M, Busnardo B. Clinical meaning of anti-thyroglobulin antibodies in differentiated thyroid cancer: a prospective study. J Nucl Med 1991;33:1478-80.
10. Hay ID, Bergstrahl EJ, Goellner JR, Eberson JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993;114:1050-8.
11. Thoresen SO, Akslen LA, Glattre E, Haldrsen T, Lund EV, Schoultz M. Survival and prognostic factors in differentiated thyroid cancer. A multivariate analysis of 1055 cases. Br J Cancer 1989;59:231-5.
12. Rubello D, Saladini G, Carpi A, Casara D. Nuclear medicine imaging procedures in differentiated thyroid carcinoma patients with negative iodine scan. Biomed Pharmacother 2000;54:337-44.
13. Casara D, Rubello D. Diagnostic scintigraphy in postoperative staging and follow-up of differentiated thyroid carcinoma. Rays 2000;25:207-19.
14. Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131 uptake in thyroid cancer. J Nucl Med 1996;37:1468-72.
15. Gasparoni P, Rubello D, LoGiudice C, Ferlin G. Potential significance of fluorine-18-deoxyglucose positron emission tomography in pulmonary metastases of differentiated thyroid carcinoma. Thyroidol, Clin Exp 1997;9:101-5.
16. Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Busnardo B. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993;34:1626-31.
17. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schica H. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm? Nuklearmedizin 1998;37:12-7.
18. 99mTc- sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997;7:327-35.
19. 18F-fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000;85:1107-13.
20. 131I scan (abstract) Eur J Nucl Med 1998;25:939.
21. 18F-fluorodeoxyglucose positron emission tomography in patients with radioiodine-nagative recurrent well-differentiated thyroid carcinoma. Ann Surg 2001;234:804-11.
22. 131I scan negative thyroid carcinoma patients with local recurrence in cervical lymph nodes. Head Neck 2001;23:94-103.
23. Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547-52.
24. Sisson JC, Ackermann RJ, Meyer MA. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 1998;383:160-3.
25. Moog F, Linke R, Manthey N, Tiling R, Knesewitsch P, Tatsch K et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 2000;41:1989-95.
26. Matthaei S, Trost B, Hamman A, Kausch C, Benecke H, Greten H et al. Effect of in vivo thyroid hormone status on insulin signalling and GLUT1 and GLUT4 glucose transport system in rat adipocytes. J Endocrinol 1995;144:347-57.
27. Saad MF, Ordonez NG, Rashid RK. Medullary carcinoma of the thyroid: a study of the clinical features and prognostic factors in 161 patients. Medicine 1984;63:319-42.
28. Lairmore TC, Wells SA Jr. Medullary carcinoma of the thyroid: current diagnosis and menagement. Semin Surg Oncol 1991;7:92-9.
29. Golzman D, Potts JT, Ridgway EC, Mallo F. Calcitonin as a tumor marker. Use of radioimmunoassy for calcitonin in the postoperative evaluation of patients with medullary thyroid carcinoma. N Engl J Med 1974;290:1035-9.
30. Rufini V, Salvatori M, Garganese MC, Di Giuda D, Maussier ML, Troncone L. Role of nuclear medicine in the diagnosis anf therapy of medullary thyroid carcinoma. Rays 2000;25:273-82.
31. Diehl M, Risse JH, Brandt-Mainz K, Ditlein M, Bohuslavizki KH, Matheja P et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 2001;28(11):1671-6.
32. Gasparoni G, Rubello D, Ferlin G. Potential role of fluorine-18- deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma. J Endocrinol Invest 1997;20:527-30.
33. Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000;27:490-6.
34. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001;28:64-71.
35. Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH Hör G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. Eur J Nucl Med 1998;25:79-83.
36. Modigliani E, Cohen R, Campos JM. Prognostic factors for survival and biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol (Oxf) 1998;48:265-73.
37. Rufini V, Festa A, Vellante E, Troncone L. Nuclear medicine imaging in medullary thyroid carcinoma. Q J Nucl Med 1996;40:19-25.
38. 99mTc-MIBI scintigraphy: an effective imaging technique in detecting loco-regional metastases of medullary thyroid carcinoma (MTC). J Nucl Med 2001;42:323.
39. Öberg K. Neuroendocrine gastrointestinal tumours. Ann Oncol 1996;7:453-63.
40. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet 1963;1:238-9.
41. Mignon M, Jensen RT, editors. Endocrine tumors of the pancreas: recent advances in research and management. Basel, Switzerland: S. Karger, 1995;23:1-482.
42. Öberg K. State of the art and future prospects in the management of neuroendocrine tumors. Q J Nucl Med 2000;44:3-12.
43. Solcia E, Kloppel G, Sobin LH. Histological typing of endocrine tumours. World Health Organization International Histological Classification of Tumours. 2nd edition. Heidelberg: Springer, 2000.
44. Rindi G, Capella C, Solcia E. Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract. Q J Nucl Med 2000;44:13-21.
45. Seregni E, Ferrari L, Stivanello M, Dogliotti L. Laboratory tests for neuroendocrine tumours. Q J Nucl Med 2000;44:22-41.
46. Eriksson B, Arnberg H, Öberg K, Hellman U, Wernstedt C, Wilander E. Chromogranins: new sensitive markers for neuroendocrine tumors. Acta Oncol 1989;28:325-9.
47. Troncone L, Rufini V. Radiolabeled metaiodobenzylguanidine in the diagnosis of neural crest tumors. In: Murray IPC, Ell PJ, editors. Nuclear medicine in clinical diagnosis and treatment. 2nd edition. Edinburgh: Churchill Livingstone, 1998;843-57.
48. 131I-metaiodobenzylguanidine in carcinoid tumours. J Nucl Biol Med 1991;35:346-8.
49. Taal BG, Hoefnagel CA, Valdés Olmos PA, Boot H, Beijnen JH. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumours. J Clin Oncol 1996;14:1829-38.
50. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP. Somatostatin receptor imaging in the localization of endocrine tumours. N Engl J Med 1990;323:1246-9.
51. Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, de Jong M et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-tyr-3-octreotide. J Nucl Med 1992;33:652-8.
52. 123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31.
53. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997;38:853-8.
54. Chiti A, Briganti V, Fanti S, Monetti N, Masi R, Bombardieri E. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. Q J Nucl Med 2000;44:42-9.
55. Schillaci O, Scopinaro F, Angeletti S, Tavolaro R, Danieli R, Annibale B et al. SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors. J Nucl Med 1996;37:1452-6.
56. 1]-octreotide. Ital J Gastroenterol Hepatol 1999;31(Suppl 2):S219-23.
57. Virgolini I, Traub T, Leimer M, Novotny C, Pangerl T, Ofluoglu S et al. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Q J Nucl Med 2000;44:50-8.
58. Strauss LG, Ponti PS. The application of PET in clinical oncology. J Nucl Med 1991;32:623-48.
59. Eriksson B, Bergström M, Örlefors H, Sundin A, Öberg K, Langström B. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Q J Nucl Med 2000;44:68-76.
60. 131I. Nuklearmedizin 1995;34:127-34.
61. 18F-Fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 1998;22:588-92.
62. Ahlström H, Eriksson B, Bergström M, Bjurling P, Langström B, Öberg K. Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 1995;195:333-7.
63. Eriksson B, Bergström M, Lija A, Ahlström H, Langström B, Öberg K. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors. Acta Oncol 1993;32:189-96.
64. 18F Dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 2001;220:373-80.
65. Örlefors H, Sundin A, Ahlström H, Bjurling P, Bergström M, Lilja A et al. Positron emission tomography with 5-hydroxytryptophan in neuroendocrine tumors. J Clin Oncol 1998;16:2534-42.
66. Anderson CJ, Pajeau TS, Edwards WB, Sherman ELC, Rogers BE, Welch MJ et al. In vitro and in vivo evaluation of copper-64-labeled octreotide conjugates. J Nucl Med 1995;39:1944-51.
67. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 2001;42:213-21.
68. 3-octreotide: first results in patients with meningiomas. J Nucl Med 2001;42:1053-6.
69. 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751-7.
70. Gross MD, Shapiro B. Clinical review 50: clinically silent adrenal masses. J Clin Endocronol Metab 1993;77:885-8.
71. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev 1995;16:460-84.
72. Corsello SM, Della Casa S, Bollanti L, Rufini V, Rota CA, Danza F et al. Incidentally discovered adrenal masses: a functional and morphological study. Exp Clin Endocrinol 1993;101:131-7.
73. Gross MD, Shapiro B, Bouffard JA, Glazer GM, Francis IR, Wilton GP et al. Distinguishing benign from malignant euadrenal masses. Ann Intern Med 1988;109:613-8.
74. Gross MD, Wilton GP, Shapiro B, Cho K, Samuels BI, Bouffard JA et al. Functional and scintigraphic evaluation of the silent adrenal mass. J Nucl Med 1987;28:1401-7.
75. Rufini V, Troncone L, Daidone SM, Corsello SM, Danza F. Role of nuclear medicine in the evaluation of silent adrenal masses. Radiol Med 1994;87:319-26.
76. 11C- metomidate. J Nucl Med 2000;41:1933-4.
77. Shapiro B, Gross MD, Shulkin B. Radioisotope diagnosis and therapy of malignant pheochromocitoma. In: Sandler MP, Coleman RE, Wacher FJ Th, Patton JA, Gottschalk A, Hoffer PB, editors. Baltimore: Diagnostic nulcear medicine. Williams and Wilkins Co, 2001.
78. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623-48.
79. 11C-metomidate. J Nucl Med 2000;41:275-82.
80. Boland G, Goldember MA, Lee MJ, Mayo-Smith WW, Dixon J, McNicholas MM et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-F-18-fluoro-2-deoxy-D-glucose. Radiol 1995;194:131-6.
81. Mac Manus MP, Hicks RJ, Matthews JP, Hogg A, McKenzie AF, Wirth A et al. High rate of unsuspected distant metastases by PET in apparent stage III non-small-cell cancer: implication for radical radiation therapy. Int J Rad Oncol Biol Physiol 2001;50:287-93.
82. 18F-fluorodeoxyglucose positron emission tomography. Am J Roentgenol 1997;168:1357-60.
83. 18F-FDG whole body positron emission tomography (PET) in the detection of unknown primary tumors. Clin Pos Imaging 2000;3:160-4.
84. Schumacher T, Brink I, Morer E, Nietzsche EU. Imaging of an adrenal cortex carcinoma and its metastasis with FDG-PET. Nukearmed 1999;38:124-6.
85. Maurea S, Mainolfi C, Bazzicalupo L, Panico MR, Imparato C, Alfano B et al. Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. Am J Roentgnol 1999;173:25-9.
86. Angeli A, Osella G, Ali A, Terzolo M. Adrenal incidentaloma: an overview of clinical and epidemiological data from the national Italian study group. Horm Res 1997;47:279-83.
87. Mantero F, Masini AM, Opocher G, Giovagnetti M, Arnaldi G. Adrenal incidentaloma: an overview of hormonal data from the national Italian study group. Horm Res 1997;47:284-9.
88. Sutton MG, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytoma. Review of 50-year autopsy series. Mayo Clin Proc 1981;56:354-60.
89. Maurea S, Klain M, Mainolfi C, Ziviello M, Salvatore M. The diagnostic role of radionuclide imaging in evaluation of patients with non-hypersecreting adrenal masses. J Nucl Med 2001;42:884-92.
90. Lawson MA. Role of molecular imaging in management of nonhypersecreting adrenal masses. J Nucl Med 2001;42:893-4.
91. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-fluorine-18-fluoro-2-deoxy-D-glucose PET. Radiol 1999;212:35-41.